Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
复制标题
DOI：
10.1200/jco.1998.16.7.2377
复制
发表时间：
1998-07-01
影响因子：
45.3
通讯作者：
Perez, EA
中科院分区：
文献类型：
--
作者：
Loprinzi, CL;Pisansky, TM;Perez, EA
目的：潮热可能是乳腺癌幸存者和接受雄激素剥夺治疗的男性的一个突出的临床问题，轶事信息表明，低剂量的相对较新的抗抑郁药文拉法辛可以消除这一临床问题。材料和方法：本研究纳入了28例连续可评估的进入II期临床试验的患者。在1周的基线期和4周的基线期，通过每日日记问卷收集潮热数据，在此期间，患者口服文拉法辛12.5 mg，每天两次。结果：58%完成研究的患者在第四个治疗周与基线周相比，热闪评分（频率乘以严重程度）降低了50%以上。在文拉法辛治疗的第四周，每周hat flash评分中位数比基线降低了55%。治疗通常耐受性良好，似乎减轻了疲劳、出汗和睡眠困难。结论：文拉法辛是一种有效的缓解潮热的新方法，值得进一步评价。(C)美国临床肿瘤学会1998。
Purpose: Hot flashes can be a prominent clinical problem for breast cancer survivors and men who undergo androgen-deprivation therapy Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem.Materials and Methods: This study included 28 consecutive assessable patients entered onto a phase II clinical trial. Hot flash data were collected by daily diary questionnaires during a 1-week baseline period and then for 4 weeks, during which time patients received venlafaxine 12.5 mg orally twice daily.Results: Fifty-eight percent of patients who completed the study had a greater than 50% reduction in hot flash scores (frequency times severity) during the fourth treatment week as compared with the baseline week. Median weekly hat flash scores were reduced by 55% from baseline during the fourth week of venlafaxine therapy. Therapy was generally well tolerated and appeared to alleviate fatigue, sweating, and trouble sleeping.Conclusion: Venlafaxine appears to represent an efficacious new method to alleviate hot flashes, Further evaluation of this compound far alleviating hat flashes is indicated. (C) 1998 by American Society of Clinical Oncology.